Effector and central memory T helper 2 cells respond differently to peptide immunotherapy

Peptide immunotherapy (PIT) offers realistic prospects for the treatment of allergic diseases, including allergic asthma. Much is understood of the behavior of naive T cells in response to PIT. However, treatment of patients with ongoing allergic disease requires detailed understanding of the respon...

Full description

Saved in:

Bibliographic Details
Published in:	Proceedings of the National Academy of Sciences - PNAS 2014-02, Vol.111 (8), p.E784-E793
Main Authors:	Mackenzie, Karen J, Nowakowska, Dominika J, Leech, Melanie D, McFarlane, Amanda J, Wilson, Claire, Fitch, Paul M, O'Connor, Richard A, Howie, Sarah E M, Schwarze, Jürgen, Anderton, Stephen M
Format:	Article
Language:	eng
Subjects:	Allergies Animals Biological Sciences Bronchoalveolar Lavage Cells Cellular biology Flow Cytometry Hypersensitivity - drug therapy Hypersensitivity - immunology Hypersensitivity - pathology Immunologic Memory - immunology Immunotherapy Immunotherapy - methods L-Selectin - immunology Lung - pathology Memory Mice Mice, Transgenic Ovalbumin - immunology Ovalbumin - therapeutic use Peptide Fragments - immunology Peptide Fragments - therapeutic use Peptides PNAS Plus Th2 Cells - cytology Th2 Cells - immunology
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Peptide immunotherapy (PIT) offers realistic prospects for the treatment of allergic diseases, including allergic asthma. Much is understood of the behavior of naive T cells in response to PIT. However, treatment of patients with ongoing allergic disease requires detailed understanding of the responses of allergen-experienced T cells. CD62L expression by allergen-experienced T cells corresponds to effector/effector memory (CD62L ˡᵒ) and central memory (CD62L ʰⁱ) subsets, which vary with allergen exposure (e.g., during, or out with, pollen season). The efficacy of PIT on different T helper 2 (Th2) cell memory populations is unknown. We developed a murine model of PIT in allergic airway inflammation (AAI) driven by adoptively transferred, traceable ovalbumin-experienced Th2 cells. PIT effectively suppressed AAI driven by unfractionated Th2 cells. Selective transfer of CD62L ʰⁱ and CD62L ˡᵒ Th2 cells revealed that these two populations behaved differently from one another and from previously characterized (early deletional) responses of naive CD4 ⁺ T cells to PIT. Most notably, allergen-reactive CD62L ˡᵒ Th2 cells were long-lived within the lung after PIT, before allergen challenge, in contrast to CD62L ʰⁱ Th2 cells. Despite this, PIT was most potent against CD62L ˡᵒ Th2 cells in protecting from AAI, impairing their ability to produce Th2 cytokines, whereas this capacity was heightened in PIT-treated CD62L ʰⁱ Th2 cells. We conclude that Th2 cells do not undergo an early deletional form of tolerance after PIT. Moreover, memory Th2 subsets respond differently to PIT. These findings have implications for the clinical translation of PIT in different allergic scenarios.
ISSN:	0027-8424 1091-6490